Compare Garmin Ltd. (GRMN) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs Natera Inc. Common Stock — how do they compare? Garmin Ltd. trades at $281.37 (market cap $53.31B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Garmin Ltd. and Natera Inc. Common Stock are close in size by market cap, and Garmin Ltd. pays a 1.52% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 84 Days and Natera Inc. Common Stock for 0 Days on average.
| GRMN | NTRA | |
|---|---|---|
Market Cap | $53.31B | $57.03B |
Volume | 778,898 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $313.16 | $425.64 |
52-Week Low | $187.10 | $179.42 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $50.82B | $56.18B |
Dividend Yield | 1.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $279.72, up 4.86% with strong earnings momentum after beating Q2 2026 EPS estimates. The stock shows bearish technical signals but maintains robust fundamentals with 24.47% net margins and consistent revenue growth from $4.9B in 2022 to $7.25B in 2025. Recent positive news includes product awards and institutional accumulation, though technical indicators suggest near-term resistance.
GRMN presents a mixed outlook: strong profitability and analyst consensus target of $320.25 offer 14.5% upside, but bearish technicals and high valuation ratios (P/E 28.53) pose risks. Investment appeal hinges on execution of 2026 revenue guidance ($7.7B) amid competitive pressures in consumer electronics.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
